What is HC Wainwright's Forecast for DRUG FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Bright Minds Biosciences to a loss of $3.15 per share, from a previous loss estimate of $5.92. The revised outlook indicates expectations for narrower losses.
• HC Wainwright maintained a Buy rating and $145 price target on DRUG. The broader analyst consensus is also positive, with an average Buy rating and $143.83 target price.
• Bright Minds reported a quarterly loss of $0.17 per share, significantly better than the $1.22 loss analysts expected. HC Wainwright projects the company could reach positive EPS of $2.41 by FY2030, although that estimate was reduced from $3.09.

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings estimates for Bright Minds Biosciences in a research report issued to clients and investors on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($3.15) per share for the year, up from their prior forecast of ($5.92). HC Wainwright currently has a "Buy" rating and a $145.00 target price on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Bright Minds Biosciences' Q4 2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($1.30) EPS, Q2 2027 earnings at ($1.57) EPS, Q3 2027 earnings at ($1.38) EPS, Q4 2027 earnings at ($1.56) EPS, FY2027 earnings at ($5.83) EPS, FY2028 earnings at ($5.04) EPS, FY2029 earnings at ($2.79) EPS and FY2030 earnings at $2.41 EPS.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its quarterly earnings data on Monday, August 17th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $1.05.

A number of other research analysts also recently commented on the stock. Zacks Research raised shares of Bright Minds Biosciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 21st. Oppenheimer downgraded Bright Minds Biosciences to a "market perform" rating in a research report on Thursday. Wall Street Zen raised Bright Minds Biosciences from a "strong sell" rating to a "sell" rating in a research note on Saturday, July 4th. Benchmark reissued a "buy" rating on shares of Bright Minds Biosciences in a research report on Thursday. Finally, Piper Sandler restated an "overweight" rating and set a $220.00 price target (up from $190.00) on shares of Bright Minds Biosciences in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $143.83.

Bright Minds Biosciences Stock Down 7.3%

Bright Minds Biosciences stock opened at $78.56 on Friday. The firm's fifty day moving average is $72.11 and its 200 day moving average is $77.11. Bright Minds Biosciences has a 52-week low of $38.00 and a 52-week high of $123.75. The company has a market cap of $764.39 million, a price-to-earnings ratio of -37.77 and a beta of -5.27.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vivo Capital LLC boosted its position in Bright Minds Biosciences by 99.4% during the 3rd quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock valued at $30,428,000 after acquiring an additional 250,045 shares in the last quarter. MPM Bioimpact LLC purchased a new position in shares of Bright Minds Biosciences in the 4th quarter valued at approximately $17,961,000. Balyasny Asset Management L.P. acquired a new stake in shares of Bright Minds Biosciences during the third quarter worth $11,339,000. Millennium Management LLC grew its stake in Bright Minds Biosciences by 376.9% during the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after purchasing an additional 152,178 shares during the last quarter. Finally, Ikarian Capital LLC boosted its position in Bright Minds Biosciences by 933.1% in the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company's stock valued at $12,441,000 after buying an additional 143,990 shares during the last quarter. 40.52% of the stock is currently owned by hedge funds and other institutional investors.

More Bright Minds Biosciences News

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across most forecast periods. The firm improved its EPS outlook for FY2026 to $(3.15) from $(5.92), FY2027 to $(5.83) from $(9.07), FY2028 to $(5.04) from $(7.93), and FY2029 to $(2.79) from $(4.04). Quarterly estimates for Q4 2026 through Q4 2027 were also raised, suggesting expectations for narrower losses. HC Wainwright Reaffirms Buy Rating for Bright Minds Biosciences
• Positive Sentiment: The analyst maintained a Buy rating and a $145 price target. The target implies substantial potential upside from the stock’s recent trading level and reinforces confidence in Bright Minds’ development and commercialization prospects. HC Wainwright Reiterates Buy Rating on Bright Minds Biosciences
• Positive Sentiment: The revised estimates point to a possible transition toward profitability. HC Wainwright forecasts positive EPS of $2.41 by FY2030, while the company recently exceeded quarterly EPS expectations, reporting a loss of $(0.17) versus the consensus loss estimate of $(1.22).
• Negative Sentiment: HC Wainwright lowered its FY2030 EPS forecast to $2.41 from $3.09. Although the estimate remains profitable, the reduction represents a longer-term downside revision and highlights continuing uncertainty around the timing and scale of Bright Minds’ earnings potential.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source